However, extensive in vitro and in vivo studies, coupled with structure–activity relationship analysis, are needed to further support this hypothesis, using biochemical assays on both CA5 isoforms and animal models of obesity and dyslipidemia. The gene discussed is CA5A; the disease is metabolic syndrome.